Financings

ADMA Biologics Inc. obtained a $6 million term loan from Hercules Technology Growth Capital Inc.

Hatteras Venture Partners closed its HVP IV fund with $125 million in total capital.

Ironwood Pharmaceuticals Inc. completed a debt offering of $175 million.

ISA Pharmaceuticals BV raised $10.5 million to fund a Phase II trial of its vaccine for cervical cancer.

Marinus Pharmaceuticals Inc. received $21 million in new Series C financing.

Senesco Technologies Inc. plans to raise about $3 million through the sale of 30 million shares.

Solstice Biologics LLC closed an $18 million Series A round for RNAi R&D.

Synageva BioPharma Corp. closed an $118 million underwritten public offering.

Deals

BioMarin Pharmaceutical Inc. acquired Zacharon Pharmaceuticals for $10 million up front with potential milestones.

Evotec AG said it partnered with Yale University to leverage Yale's science and Evotec's drug discovery infrastructure.

GlycoVaxyn AG is collaborating with Janssen Pharmaceuticals Inc. to develop a multivalent bacterial vaccine.

Heptares Therapeutics Ltd. signed a deal with Cubist Pharmaceuticals Inc. for its GPCR technology.

MacroGenics Inc. signed a potential $1 billion deal with Gilead Sciences Inc., which will deploy the company's Dual‐Affinity Re‐Targeting technology for drugs directed at up to four targets.

Onconova Therapeutics Inc. partnered with GVK BIO to develop two targets through clinical stage.

OPKO Health Inc. will acquire Cytochroma Ltd. for undisclosed terms.

Pepscan Therapeutics BV signed a research deal with an undisclosed U.S.-based antibody discovery company.

Verastem Inc. partnered with Laboratory Corp. of America Holdings to validate biomarkers.

. . . And More

See BioWorld Today for extensive coverage of the J.P. Morgan Healthcare Conference held last week.

Biogen Idec Inc. submitted a biologics license application to the FDA for recombinant Factor IX Fc fusion protein for the treatment of hemophilia B.

GTC Biotherapeutics Inc. changed its name to rEVO Biologics.

Kinex Pharmaceuticals converted from a Limited Liability Corporation into a C-Corporation.

Trius Therapeutics Inc. said the FDA designated tedizolid phosphate as a Qualified Infectious Disease Product, in both its oral and intravenous formulations.